These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15965429)

  • 1. Decision points for the initiation of systemic treatment for psoriasis.
    Feldman SR; Koo JY; Menter A; Bagel J
    J Am Acad Dermatol; 2005 Jul; 53(1):101-7. PubMed ID: 15965429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
    Puig L; Bordas X; Carrascosa JM; Daudén E; Ferrándiz C; Hernanz JM; López-Estebaranz JL; Moreno JC; Sánchez-Carazo JL; Vanaclocha F; Vázquez-Veiga H;
    Actas Dermosifiliogr; 2009 May; 100(4):277-86. PubMed ID: 19463230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of psoriasis: an algorithm-based approach for primary care physicians.
    Pardasani AG; Feldman SR; Clark AR
    Am Fam Physician; 2000 Feb; 61(3):725-33, 736. PubMed ID: 10695585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PsoReg--the Swedish registry for systemic psoriasis treatment. The registry's design and objectives.
    Schmitt-Egenolf M
    Dermatology; 2007; 214(2):112-7. PubMed ID: 17341858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis].
    Ara M; Pérez A; Ferrando J
    Actas Dermosifiliogr; 2011 Nov; 102(9):706-16. PubMed ID: 21600532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinician's paradigm in the treatment of psoriasis.
    Lebwohl M
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S59-69. PubMed ID: 15968265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes associated with the use of biologic agents in moderate to severe psoriasis.
    Price J; Bhosle M; Feldman SR; Balkrishnan R
    J Drugs Dermatol; 2007 Mar; 6(3):259-67. PubMed ID: 17373187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of treatment on quality of life in psoriasis patients.
    Prins M; Krabbe PF; Swinkels QO; de Boo T; van de Kerkhof PC; van der Valk PG
    Acta Derm Venereol; 2005; 85(4):304-10. PubMed ID: 16191850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and costs of severe psoriasis: the role of new biologics.
    Feldman SR; Pearce DJ
    Expert Rev Pharmacoecon Outcomes Res; 2004 Oct; 4(5):573-9. PubMed ID: 19807550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic treatments for severe pediatric psoriasis: a practical approach.
    Marqueling AL; Cordoro KM
    Dermatol Clin; 2013 Apr; 31(2):267-88. PubMed ID: 23557655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment goals in psoriasis.
    Reich K; Mrowietz U
    J Dtsch Dermatol Ges; 2007 Jul; 5(7):566-74. PubMed ID: 17610606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriasis assessment tools in clinical trials.
    Feldman SR; Krueger GG
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii65-8; discussion ii69-73. PubMed ID: 15708941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and therapeutic evaluation of patients with moderate to severe psoriasis in Spain: the secuence study.
    Hernánz JM; Sánchez-Regaña M; Izu R; Mendiola V; García-Calvo C
    Actas Dermosifiliogr; 2012 Dec; 103(10):897-904. PubMed ID: 23157919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.
    Schöffski O; Augustin M; Prinz J; Rauner K; Schubert E; Sohn S; Reich K
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):209-18. PubMed ID: 17338796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Implementation of the S3-guidelines for systemic and UV therapy of moderate to severe psoriasis vulgaris by an algorithm].
    Weisenseel P; Kuznetsov AV; Prinz JC
    J Dtsch Dermatol Ges; 2007 Aug; 5(8):683-8. PubMed ID: 17659043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
    Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
    J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Topical corticosteroids and corticosteroid sparing therapy in psoriasis management].
    Sukarovska BG; Lipozencić J; Vrzogić P
    Acta Med Croatica; 2007 Sep; 61(4):375-81. PubMed ID: 18044472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What are the objectives of moderate to severe psoriasis treatment?].
    Ortonne JP
    Ann Dermatol Venereol; 2008 Jul; 135 Suppl 5():S281-4. PubMed ID: 18721665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists.
    Patel V; Horn EJ; Lobosco SJ; Fox KM; Stevens SR; Lebwohl M
    J Am Acad Dermatol; 2008 Jun; 58(6):964-9. PubMed ID: 18378352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis--recent advances in understanding its pathogenesis and treatment.
    Krueger G; Ellis CN
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S94-100. PubMed ID: 15968269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.